Determination of Specificity and Sensitivity of Anti-RA 33 in Diagnosis of Early Rheumatoid Arthritis

Mahin Lashkari¹, Akram Noori¹, Fatemeh Hajiimanouchehrí², Sonia Oveisi¹ & Amir Mohammad Kazemifar¹

¹ Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
² Pathology Department, Qazvin University of Medical Sciences, Qazvin, Iran

Correspondence: Akram Noori, MD, Assistant Professor Rheumatology, Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. E-mail: anoori_92@gmail.com

Received: February 18, 2014    Accepted: April 28, 2014    Online Published: May 28, 2014

doi:10.5539/gjhs.v6n4p292    URL: http://dx.doi.org/10.5539/gjhs.v6n4p292

Abstract

Background: Rheumatoid arthritis is a chronic inflammatory disease with uncertain etiology. It is characterized by symmetric polyarthritis in peripheral joints. Its diagnosis is based on clinical findings and serologic tests. However, its diagnosis is rarely conclusive in early course of the disease. So, its early diagnosis could be difficult. The present study was designed to evaluate the role of anti -RA33; an auto-antibody against RA33 in early diagnosis of the disease.

Materials and Methods: forty three patients with RA who had been visited in a rheumatology clinic were randomly selected. Their disease has been diagnosed by a rheumatologist. They served as the case group. 55 persons were also chosen from healthy individuals who had attended in other clinic. They served as control. Their age and sex were matched with the case group. Anti-RA33 and RF titers were measured in their blood sample using standard methods.

Findings: RF and anti-RA33 titers had significant correlation in the case group (p=0.015). Anti -RA33 test had 98% sensitivity, 20% specificity, 50% positive predictive value, and 90% negative predictive value.

Conclusion: Anti -RA33 could have diagnostic and prognostic importance in diagnosis and evaluation of patients with RA, and its differentiation from other small joint disorders, particularly when the other serologic tests are negative.

Keywords: rheumatoid arthritis, anti-RA-33, rheumatoid factor, diagnosis

1. Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease with unknown etiology characterized by symmetric peripheral polyarthritis. RA is the most common form of chronic inflammatory arthritis. It often results in joint damage and physical disability. It is a systemic disease with a variety of extra-articular manifestations including fatigue, subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, vasculitis, and hematologic abnormalities (McInnes & Schett, 2011).

The incidence of RA rises in ages between 25 and 55 years, and then reaches to plateau until the age 75, and afterward decreases. The presenting symptoms of RA typically result from inflammation of the joints, tendons, and bursas. The patients often complain from early morning joint stiffness that lasts more than 1 hour and improves with physical activity. The small joints of the hands and feet are the earliest involved joints. The initial pattern of joint involvement may be mono-articular, oligo-articular (less than 4 joints), or poly-articular (more than 5 joints); usually with symmetric distribution (Firth, 2011; Nyhäll-Wählin et al., 2011).

Diagnosis of RA is based on its typical signs and symptoms, with laboratory and radiographic confirmation. In 2010, a collaborative effort between the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) led to revision of the 1987 ACR classification criteria for diagnosis of RA to improve its early diagnosis with the goal of identifying patients who would benefit from early performance of disease-modifying therapies (Thabet et al., 2012). However, some patients may remain undiagnosed, do not treat at appropriate time to reach the disease remission or low disease activity, and could face with adverse effects of more potent therapeutic agents or complications of the disease. Consequently, determination of a more
conclusive test for diagnosis of RA is superlative. The autoantibody reactivity defined as anti-RA 33 is against a component of the spliceosome which is the heterogeneous ribonucleoprotein complex 36-kDa A2 protein. The antigen that is associated with mRNA involve in regulation of pre-mRNA splicing, mRNA transport and translation. The anti-RA 33 antibodies can be found in the tumor necrosis factor-transgenic mice that develop spontaneous arthritis. However, they may contribute in pathogenesis of diseases in a nonspecific manner. An exception is auto antibodies against hnRNP-A2, which appears to have some relevance with pathogenesis of RA. Hn RNP-A2 is found in skin, lymphoid tissues, brain, and reproductive organs with highest expression levels (Conrad et al., 2010). Anti-RA 33 antibodies occur in approximately one third of patients with RA. Its level remains normally constant in the course of the disease (Steiner & Smolen, 2002; Duskin & Eisenberg, 2005).

Because anti-hnRNPA2 is rarely seen in osteoarthritis, reactive arthritis, ankylosing spondylitis or psoriatic arthritis, it can be helpful for differential diagnosis of these diseases with RA, particularly in patients who have negative RF and/or ACPA tests. Specificity of Anti-hn RNPA2 antibodies is approximately 90% for RA, which is somewhat lower than the specificity of ACPA or Ig M-RF. Similar to RF and ACPA, anti-hnRNPA2 antibodies may appear in the earlier stages of the disease. They do not correlate with Ig M-RF or ACPA and are also not associated with radiographic progression of the disease, but rather seem to characterize patients with more favorable prognosis (Nell et al., 2005). In some studies, it is reported that anti-RA33 could be seen in 1% of normal population. It has also been suggested that it can be measured in early stages of RA (van Boekel et al., 2002; Fritsch et al., 2002; Mediwake et al., 2001).

There are not sufficient reports about the value of anti-RA33 in diagnosis of RA. The present study was designed to evaluate the role of anti-RA33 in early diagnosis of RA in comparison with RF.

2. Materials and Methods

Forty three patients with RA whose disease was diagnosed by a rheumatologist were enrolled in the present study. They were randomly selected from a rheumatology OPD clinic in Qazvin city, Iran. They were assigned as case group. 55 apparently healthy individuals were also selected from attendants of an OPD clinic. They were assigned as control group. Inclusion criterion was RA which had been diagnosed by a rheumatologist. An exclusion criterion was suffering from rheumatologic disorders other than RA.

Details of clinical symptoms, the disease duration, morning stiffness, extra-articular findings, number of the affected joints and lab test results have been collected from the patients' medical records. Furthermore, their age, gender and the level of education were informed.

The level of anti-RA33 was compared between the groups. It was measured by ELISA. The cut-off point of the level was drawn, in which the sensitivity, specificity, and negative and positive predictive values of the test have been calculated, as well as its age correlation, and its association with RF.

The study has been approved by local ethical committee of Qazvin University of Medical Sciences, Iran. All of the studied persons provided informed consent for participation in the study.

3. Results

The current study was performed on 98 persons included 43 patients and 55 normal subjects, among whom 21 were male. There was no significant difference between the groups in gender distribution, but in their age, most of the subjects in case group were 30–49 years old, and in their level of education, most patients had high school education or less, whereas a significant number of subjects in control group had higher education (Table 1).

In patients group, the mean number of the affected joints was 14.79±6.33. The mean duration of the disease was 10.53±10.29 months. The other findings about the case group were shown in Table 2. The RF titer was 57.16±67.35 in the case group. The mean concentration of anti RA33 was 28.34±16.21 IU/mL. As it has been demonstrated in Table 3, there was significant difference between the groups in concentration of RF and anti-RA 33.

There was significant and positive relationship between age and RF titer (P=0.001), while there was no significant relationship between age and anti-RA33 titer (Table 4). There was also significant and positive relationship between RF and Anti RA33 titers (P=0.015). As it can be seen in chart 1, if the cutoff of Anti-RA33 is set at 11.9, it has 98% sensitivity for recognizing patients with RA. The positive and negative predictive values of the test were 50% and 90%, respectively.